22 Apr 2015
A study of 60 patients in France with advanced medullary thyroid cancer who were treated with the kinase inhibitor vandetanib (Capresela, AstraZeneca) outside of a clinical trial showed that the drug could be an option for some patients.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024